APRIL 2024
A Comparative Analysis of the Therapeutic Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate versus Budesonide and Tiotropium Dihydrate in Managing COPD Exacerbations, Lung Function, Symptoms, and Quality of Life: A Multicenter Study
1Dr Aqsa Sadaf, 2Dr.Ghulam Abbas Tahir 3Yasir Yaqoob,4Dr.Ahmad Zeeshan, 5Dr .irfan Haider , 6Dr Asma Qibtia
1Postgraduate resident (Internal medicine MU-3) Faisalabad Medical University, Faisalabad
2Assistant professor medicine , Faisalabad medical university, Faisalabad.
3Assistant professor medicine , Faisalabad medical university, Faisalabad
4Assistant professor medicine , Faisalabad medical university, Faisalabad.
5Senior registrar medicine, allied hospital Faisalabad
6Postgraduate Resident (Internal Medicine MU-3) Faisalabad Medical University, Faisalabad
ABSTRACT
Background: Chronic Obstructive Pulmonary Disease (COPD) poses a substantial global health burden, necessitating effective therapeutic interventions. This study undertakes a comparative analysis of the therapeutic efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) against Budesonide and Tiotropium Dihydrate (BUD/TIO) in addressing COPD exacerbations, lung function, symptoms, and overall quality of life.
Aim: The primary aim of this multicenter research was to systematically associate medical outcomes and benefits of BGF and BUD/TIO in the management of COPD exacerbations. The study sought to assess their impact on lung function, signs, and overall quality of life experienced by individuals having COPD.
Methods: A multicenter, randomized, double-blind, parallel-group design was employed, involving COPD patients recruited from diverse demographic backgrounds. Applicants were randomly allocated to either BGF or BUD/TIO group, and treatment efficacy was evaluated over a specified duration. Lung function assessments, symptom monitoring, and quality of life measurements were conducted using standardized protocols.
Results: The analysis revealed notable differences in therapeutic efficacy between BGF and BUD/TIO. BGF demonstrated superior outcomes in managing COPD exacerbations, significantly improving lung function parameters, alleviating symptoms, and enhancing the overall quality of life compared to the BUD/TIO group. The results indicated a more comprehensive and effective approach to COPD management with the use of BGF.
Conclusion: This multicenter study provides compelling evidence supporting the enhanced therapeutic efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate over Budesonide and Tiotropium Dihydrate in managing COPD exacerbations. The observed developments in lung function, symptom relief, and overall quality of life underscore potential of BGF as a more effective therapeutic option for individuals with COPD.
Keywords: COPD, Budesonide/Glycopyrronium/Formoterol Fumarate, Budesonide and Tiotropium Dihydrate, Multicenter Study, Therapeutic Efficacy, Lung Function, Symptoms, Quality of Life.